Inhibikase Therapeutics
IKT
104 hedge funds and large institutions have $193M invested in Inhibikase Therapeutics in 2026 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 38 increasing their positions, 14 reducing their positions, and 8 closing their positions.
388% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 8
171% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 14
41% more funds holding
Funds holding: 74 → 104 (+30)
11% less capital invested
Capital invested by funds: $218M → $193M (-$24.7M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
54.35% less ownership
Funds ownership: 141.56% → 87.21% (-54%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.32M |
| 2 |
Millennium Management
New York
|
+$4.9M |
| 3 |
KCM
Kalehua Capital Management
Dallas,
Texas
|
+$3.68M |
| 4 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
+$3.34M |
| 5 |
SC
SummitTX Capital
Fort Worth,
Texas
|
+$2.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$5.52M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.82M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$2.59M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.47M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.18M |
IKT Hedge Fund Activity: Q1 2026 in Review
104 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q1 2026, worth a combined $193M — down 11% from $218M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new IKT positions and 8 closed out — a net gain of 31 holders — while 38 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $5.32M. The largest seller was Perceptive Advisors, cutting an estimated $5.52M.
- 104 institutional investors held Inhibikase Therapeutics (IKT) as of Q1 2026, up from 74 in Q4 2025.
- Funds reported $193M of Inhibikase Therapeutics stock for Q1 2026, down 11% quarter-over-quarter.
- 39 funds opened new Inhibikase Therapeutics positions in Q1 2026 and 8 closed out, a net change of +31 holders.
- The largest Inhibikase Therapeutics buyer in Q1 2026 was BlackRock, an estimated $5.32M added.
- The largest Inhibikase Therapeutics seller in Q1 2026 was Perceptive Advisors, an estimated $5.52M sold.
Based on aggregated 13F filings for Q1 2026.